Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

In Situ Genetic Engineering Facilitates MMP-9-Responsive TIMP1 Release Through Proteolytic Cleavage to Boost Diabetic Wound Healing.

Created on 28 Sep 2026

Authors

Yuan Zhang, Jiani Deng, Man Yee Cheung, Tingting Fu, Xufeng Qi, Dongqing Cai, Jianmin Sun, Gang Lu, Peng Shi, Wai-Yee Chan, Xu Li, Hui Zhao

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e24328. Sep 27, 2026. Epub Sep 27, 2026.

Abstract

Diabetic Foot Ulcer (DFU), a severe chronic diabetes complication with low healing and high recurrence rates, is a major global health challenge. Overexpression of matrix metalloproteinase-9 (MMP-9) and the consequent MMP-9/TIMP1 (tissue inhibitor of metalloproteinase 1) imbalance delays healing by degrading the extracellular matrix, impairing granulation tissue formation, and exacerbating inflammation. Conventional therapies do not dynamically respond to fluctuating protease levels in chronic wounds. This study introduces an MMP-9-responsive protein release system (M9RR), where the therapeutic protein (i.e., TIMP1) is linked to a membrane-anchoring domain at its C-terminus via an MMP-9-cleavable peptide, thereby exposing the fusion protein to the extracellular side of cell membranes. The system enables targeted release of TIMP1 in high-MMP-9 microenvironments, thereby neutralizing excessive MMP-9 activity. In vitro, M9RR demonstrates MMP-9 specificity, broad mammalian cell applicability, and protection of HaCaT keratinocytes and BJ fibroblasts from MMP-9-induced damage. In db/db diabetic mice, the MMP-9-responsive TIMP1 release system (TIMP1M9RR) significantly improves wound contraction, granulation tissue formation, epithelial regeneration, and collagen remodeling. Additionally, a cryomicroneedle (CryoMNs)-based co-delivery system for basic fibroblast growth factor (bFGF) and TIMP1M9RR shows effective diabetic wound healing. This modular M9RR system offers a precise, adaptive therapeutic strategy for DFU and holds promise for other MMP-related diseases.

PMID:
42801572
Bibliographic data and abstract were imported from PubMed on 28 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 16
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement